Similarly, the phase Ib JAVELIN trial (NCT01772004) studied avelumab monotherapy in MBC (N = 168), including 72 women with HR+/HER2− BC, with an ORR of 2.8% in patients without PD-L1 pre-selection [16]. This evidence concerns the gene CD274 and breast cancer.